CALM Psychotherapy in Patients With Metastatic Cancer in Chile
Preliminary Efficacy and Acceptability of CALM Psychotherapy in Chile
Fundacion Arturo Lopez Perez
34 participants
Oct 14, 2022
INTERVENTIONAL
Conditions
Summary
Patients with metastatic cancer experience multidimensional challenges that increase the risk of emotional distress, which must be addressed by the health team. Chile lacks evidence on effective therapeutic interventions in this population. CALM is a brief, individual (with the presence of a caregiver in one or more sessions) and evidence-based psychotherapy developed at The Princess Margaret Cancer Center. It consists of an intervention of 3 to 6 psychotherapy sessions over a period of 3 to 6 months. The Global CALM program aims to expand CALM research around the world, a program to which FALP has subscribed. Objective: To evaluate the preliminary efficacy of CALM in a sample of patients with metastatic cancer in Chile. Phase 2 study of preliminary, pseudo-experimental efficacy, without a control group. The study will be carried out in Falp and Corporación Valientes.
Eligibility
Inclusion Criteria4
- be ≥18 years of age;
- be fluent in Spanish;
- be able to give informed consent; and
- have received a diagnosis of advanced or metastatic solid tumor cancer with a reduced life expectancy but greater than six months.
Exclusion Criteria4
- significant verbal communication difficulties;
- cognitive impairment indicated by the clinical team or in the patient's file.
- Patients currently in psychotherapy.
- Active suicidal ideation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
psychotherapy sessions
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06501261